CVS Adds Zepbound and Lilly's Pill, LLY Hits $1,082.92
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
eli-lillyglp-1
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
CVS Health announced on 28 May 2026 that it will restore coverage of Eli Lilly's obesity drug Zepbound on October 1. The pharmacy benefit manager will also start covering Lilly’s newly approved oral obesity medication, Foundayo, starting June 1. The decision immediately reverses a previous formulary exclusion and significantly broadens patient access to two of the most effective weight-loss treatments. As of 11:11 UTC today, Eli Lilly's stock traded at $1,082.92, reflecting a 1.68% single-day gain from the news. The move comes as managed care organizations face mounting pressure to cover the costly but transformative GLP-1 drug class.
The GLP-1 market has evolved from a diabetes treatment into a dominant force in global pharmaceuticals. The class, which includes drugs from Novo Nordisk and Eli Lilly, surpassed $50 billion in annual sales in 2025. This expansion forced a critical decision for major PBMs like CVS Caremark, Express Scripts, and OptumRx: pay for high-cost therapies or risk losing members to competitors offering broader coverage.
The current macro backdrop features persistent inflationary pressures in healthcare services. The core PCE index remains above the Federal Reserve's 2% target, complicating payer budgets. High interest rates have also increased the cost of carrying pharmacy inventory, pressuring supply chain economics.
CVS's reversal was triggered by a combination of competitive pressure and clinical evidence. Rival PBMs began selectively covering these drugs to attract large employer groups. Simultaneously, a cascade of cardiovascular outcome data published throughout 2025 demonstrated that drugs like Zepbound reduced major adverse cardiac events, transforming them from lifestyle medications into preventive care tools. This shifted the cost-benefit analysis for payers.
Eli Lilly's stock reacted positively to the coverage announcement. Shares gained 1.68% to reach $1,082.92 in morning trading, approaching the session's high of $1,093. This adds to a substantial year-to-date rally for the pharmaceutical giant, which has significantly outperformed the broader S&P 500 Health Care sector index.
The financial magnitude of CVS's decision is underscored by drug pricing. Zepbound carries a U.S. list price of approximately $1,300 per month. Foundayo, as an oral therapy, is expected to be priced at a 20-30% discount to injectable competitors, still representing an annual cost exceeding $10,000 per patient.
| Metric | Before Announcement (28 May Open) | After Announcement (11:11 UTC) |
|---|---|---|
| LLY Share Price | ~$1,065 | $1,082.92 |
| Intraday Gain | — | +1.68% |
| Market Cap Increase | — | ~$10.5 billion |
The potential patient population is vast. Over 40% of American adults are classified as obese, representing a addressable market for these drugs exceeding 100 million people. Analyst consensus projects the global obesity drug market will exceed $100 billion annually by 2030, with Lilly and Novo Nordisk controlling over 90% of the current market share.
The direct beneficiary is Eli Lilly. Expanded formulary access accelerates the path to peak sales for both Zepbound and Foundayo, potentially adding billions to annual revenue. Companies in the pharmaceutical supply chain, such as drug ingredient manufacturer Catalent and delivery device maker West Pharmaceutical Services, also stand to gain from increased production volumes.
Conversely, the decision pressures other healthcare subsectors. Traditional diabetes and cardiovascular drugmakers face displacement risk as GLP-1 drugs demonstrate superior outcomes. Medical device companies focused on bariatric surgery may see procedure volumes plateau. Health insurers initially bear the brunt of higher drug costs, though they may offset this through premium increases and tighter management of treatment duration.
A key counter-argument is the sustainability of payer coverage. PBMs could impose strict prior authorization criteria, step therapy mandates, or limited duration benefits to control costs, capping the drugs' commercial uptake. The long-term budgetary impact on Medicare and Medicaid remains a significant political and fiscal risk not yet resolved.
Institutional positioning has been decisively net long Lilly and Novo for over two years. Recent 13F filings show hedge funds and asset managers increasing exposure to the pure-play obesity drug innovators while shorting legacy healthcare providers with high exposure to obesity-related comorbidities. Fund flow data indicates capital rotation out of consumer staples and into healthcare innovators.
The next immediate catalyst is the official June 1 launch of Foundayo coverage on the CVS formulary. Initial prescription fill data for the first two weeks will be a critical indicator of demand. The following major event is the October 1 reactivation of Zepbound coverage, which will test the system's capacity for high-volume injectable therapies.
Investors should monitor the Q2 2026 earnings calls for CVS Health and Eli Lilly in late July for updated guidance on the financial impact. The Centers for Medicare & Medicaid Services will also issue its final 2027 Medicare Part D rules in the fall, which may clarify reimbursement pathways for obesity drugs in federal programs.
Key technical levels for LLY include immediate resistance at the $1,100 psychological barrier, with stronger resistance near the all-time high of $1,125. Support rests at the 50-day moving average, currently near $1,040. A sustained break above $1,100 on high volume would confirm the bullish trend continuation, while a failure to hold $1,040 would signal a deeper correction.
Formulary inclusion typically lowers patient copayments, but the final cost depends on the specific pharmacy benefit plan. Most plans use tiered formularies, and GLP-1 drugs are often placed on a specialty tier with higher cost-sharing. Patients may still pay hundreds of dollars monthly, though it is less than the full $1,300 list price. Savings programs from manufacturers can further reduce costs for commercially insured patients.
Foundayo is distinct from older medications like phentermine. It is a GLP-1 receptor agonist in oral form, sharing a similar mechanism of action with injectables like Wegovy and Zepbound but with the convenience of a pill. Clinical trial data showed superior weight loss efficacy—averaging 15-20% of body weight—compared to historical oral drugs, which typically achieved 5-10% weight reduction. Its main competitor is Novo Nordisk's oral semaglutide, Rybelsus.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.